Cigna Group sets 10%-14% adjusted EPS growth target
A 10%-14% long-term average annual adjusted EPS growth target accompanies a $3 billion multi-year modernization and productivity initiative series.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
The Cigna Group introduced its “Lead to One” vision at Investor Day, focusing on affordability and personalized care across the health care continuum. Company leaders described applying the capabilities of Evernorth Health Services and Cigna Healthcare to complex-care needs, and using data, clinical expertise and AI to identify needs earlier and personalize support. The company reaffirmed its 2026 financial guidance and set a long-term average annual adjusted EPS growth target of 10%-14%.
It announced a $3 billion multi-year series of modernization and productivity initiatives focused on streamlining processes, AI-enabled tools, and supplier and vendor management. Ann M. Dennison, executive vice president and chief financial officer, said the initiatives are expected to self-fund and fuel performance. The Cigna Group Foundation announced a $10.5 million, three-year grant program to expand community support for patients and caregivers and address non-clinical treatment barriers, including through care navigation, education and peer support. The company’s outlook includes expected future share repurchases and anticipated 2026 dividends; future dividend declarations are subject to Board approval.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Long-term average annual adjusted EPS growth target: 10%-14%
Modernization and productivity initiatives: $3 billion
Foundation grant program: $10.5 million
+2 more
5 metrics
Long-term average annual adjusted EPS growth target
10%-14%
Long-term target
Modernization and productivity initiatives
$3 billion
Multi-year series
Foundation grant program
$10.5 million
Three-year program
Grant program duration
3 years
The Cigna Group Foundation community-support program
Financial target period
2026–2030
Targets are through year-end 2030 unless otherwise noted
Key Terms
adjusted EPS, medical care ratio, equity method of accounting, capital-light model
4 terms
adjusted EPS financial
"long-term average annual adjusted EPS growth target"
Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.
medical care ratio financial
"projected medical care ratio for 2026"
Medical care ratio is the share of an insurer’s revenue that goes to paying policyholder medical claims and related care rather than administrative costs or profit. Think of it like the portion of a grocery budget spent on food versus other household bills: a higher ratio means more money is being spent directly on care, which can signal higher claims and lower underwriting profit, while a lower ratio can indicate better profitability but may raise regulatory or quality concerns. Investors use it to assess an insurer’s pricing, cost control and financial health.
equity method of accounting financial
"using the equity method of accounting"
An equity method of accounting is the way a company reports its financial interest in another business when it has significant influence but not full control, typically owning between about 20% and 50% of the voting stock. Instead of listing the investment at purchase cost or consolidating every line item, the investor records its proportional share of the other company’s profits or losses and adjusts the investment value for dividends or impairments, so investors see the economic impact of that stake. This matters because it changes reported earnings and asset values in a way that reflects ongoing performance—similar to showing your share of a small business’s monthly profit on your own books rather than just the amount you originally paid for your share—and helps gauge how much influence that stake has on the investor’s financial health.
capital-light model financial
"capital flexibility enabled by the Company’s capital-light model"
A capital-light model is a way of running a business that avoids large upfront investments in factories, equipment or real estate by using outsourcing, licensing, digital delivery or partner networks instead. For investors it matters because such companies often need less cash to grow, can scale faster and carry lower fixed costs—potentially boosting returns—while being more exposed to partner risk and competitive pressure, like renting tools instead of buying them.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What long-term adjusted EPS growth target did CI announce?
The Cigna Group set a 10%-14% long-term average annual adjusted EPS growth target.
How large is CI's new patient-support grant program?
The Cigna Group Foundation announced a $10.5 million, three-year grant program to expand community support for patients and caregivers. Its focus includes care navigation, education, peer support, mental health resources and assistance with essential social needs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 30, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (860 ) 226-6000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
Outlook and Investor Day Information
On September 30, 2026, The Cigna Group (referred to as the “Company,” “we,” “us” or “our”) issued a press
release noting that the Company will host its Investor Day, both in person and virtually, beginning at approximately 8:30 a.m. Eastern Time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”). During
Investor Day, as well as in meetings with investors and analysts over the next several weeks, Company officials expect to reaffirm the following full year 2026 outlook:
| • |
consolidated adjusted revenues of approximately $280 billion,
|
| • |
consolidated adjusted income from operations on a per share basis (“adjusted earnings per share” or “adjusted EPS”) of at least $30.45,
|
| • |
Evernorth Health Services adjusted income from operations of at least $6.9 billion,
|
| • |
Cigna Healthcare adjusted income from operations of at least $4.55 billion, and
|
| • |
Cigna Healthcare medical care ratio of 83.7% to 84.7%.
|
Company officials also expect to provide a long-term average annual adjusted EPS growth target of 10-14%.
The Company previously discussed its full year 2026 outlook in its press release dated July 30, 2026 and during the related investor conference call. The press release
and the conference call transcript are available on the Investor Relations page of the Company’s website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made.
The Investor Day presentations are expected to begin on September 30, 2026 at approximately 8:30 a.m. Eastern Time and conclude by 12:30 p.m. Eastern Time. Investors and
analysts are invited to listen to the presentation free over the Internet via webcast by visiting https://www.thecignagroupinvestorday.com. The Investor Relations section of the Company’s website will also contain materials used
during and relating to the Investor Day presentations, including definitions of certain metrics not determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and reconciliations of certain
historic non-GAAP metrics to the most directly comparable GAAP measures.
Definitions and Financial Information
Adjusted revenues is used by the Company’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total
revenues excluding the following adjustments: special items and the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that
management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future
underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues.
Adjusted income (loss) from operations is a principal financial measure of profitability used by the Company’s management because it presents the underlying results of
operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income (or income before taxes less
pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Company’s share of certain investment results of its
joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due
to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in
accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.
Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income or adjusted revenues to total revenues on a
forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various
factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.
The Cigna Healthcare medical care ratio represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or
experience-rated funding arrangements. Changes in percentages may be expressed in basis points.
The Company’s outlook excludes the potential effects of any business combinations that may occur after the date of this Report. The Company’s outlook includes the
potential effects of expected future share repurchases and anticipated 2026 dividends.
The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination
that the declaration of dividends remains in the best interests of the Company and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of
operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.
The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of
capital. The share repurchase program may be affected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated
transactions. The program may be suspended or discontinued at any time.
This information, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Report, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Press release dated September 30, 2026
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL).
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Report, and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking
statements may include, among others, statements concerning our projected adjusted revenue for 2026; projected adjusted income from operations for 2026 on a per share and segment basis, projected medical care ratio for 2026; projected adjusted
earnings per share outlook on a long-term basis; projected capital deployment, including share repurchases and future dividends, including projected shareholder dividends for 2026; and other statements regarding the Company’s future beliefs,
expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate,"
"predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or
implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result
in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly
changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain
relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to
expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential
liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who
participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy,
security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly
maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine
learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect
our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative
to expectations; which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on
employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the
future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of
www.thecignagroup.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions
that are difficult to predict or quantify. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
THE CIGNA GROUP
|
||
|
Date: September 30, 2026
|
By:
|
/s/ Ann M. Dennison
|
|
Ann M. Dennison
|
||
|
Executive Vice President and Chief Financial Officer
|
||
Exhibit 99.1
 |
 |
The Cigna Group Hosts 2026 Investor Day;
Introduces “Lead to One” to Drive Durable Growth
Through Complex Care Leadership and Differentiated Capabilities
|
•
|
Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned where health care costs are concentrating
with multiple avenues for growth
|
|
•
|
Announces “Lead to One” vision, unifying all colleagues around delivering personalization at scale to improve affordability and the patient experience
|
|
•
|
Distinct, industry-leading capabilities in complex care, powered by clinical expertise, data, technology and AI
|
|
•
|
Announces $3B multi-year modernization and productivity initiatives to fuel performance
|
|
•
|
Reaffirms 2026 full-year financial guidance and provides long-term financial growth target of 10-14% adjusted EPS CAGR through 2030
|
BLOOMFIELD, Conn., Sept. 30, 2026 – Today, at its
Investor Day, The Cigna Group (NYSE: CI) will outline its strategy to improve affordability and personalization across the health care continuum. Enterprise leaders will detail how the Company’s deliberately shaped portfolio, differentiated
leadership in complex care, and disciplined execution position it to deliver durable growth, robust operating cash flow, and enhanced shareholder returns.
“We are proud to announce ‘Lead to One,’ our vision for the future of healthcare through personalization at scale. This unifies direction for our enterprise and positions
The Cigna Group for continued success as we work to improve the health of the diverse range of customers we serve,” said Brian Evanko, President and Chief Executive Officer of The Cigna Group. “We are uniquely positioned in the fastest-growing
areas of health care, with a distinct ability to serve patients with complex needs through the combined capabilities of our Evernorth Health Services and Cigna Healthcare businesses. By building on our growth platforms, scaling our differentiated
capabilities, and executing with discipline, we are well positioned to deliver durable earnings growth, create long-term shareholder value, and improve affordability and outcomes for those we are privileged to serve.”
Introduces “Lead to One” Vision to Drive Durable Growth
The Cigna Group is focused on transforming health care by improving affordability and delivering personalization for all customers across the care continuum. Lead to One
is delivered through the strategic growth framework leaders will outline today:
|
•
|
Deliver core growth: Build on the strong
foundation of a deliberately shaped portfolio — including Cigna Healthcare and Evernorth’s Specialty & Care Services and Pharmacy Benefit Services — to drive growth.
|
|
•
|
Leverage distinct capabilities: Apply
industry-leading complex care capabilities, enabled by clinical expertise, data, technology and AI.
|
|
•
|
Execute with discipline: Maintain a clear vision, consistent execution, operational excellence, a culture of innovation and disciplined capital stewardship.
|
1
Deliver core growth
The Cigna Group's businesses are connected through shared clinical expertise, data, customer relationships, and distribution capabilities, creating multiple avenues for
growth and value creation. This deliberately built foundation is aligned to attractive, growing segments of health care where the Company possesses meaningful scale, differentiated capabilities, and opportunities for continued expansion.
Leverage distinct capabilities
Complex care is rarely defined by a single diagnosis, medication or episode of care. Patients with complex needs often require support across multiple conditions,
specialty and traditional medications, behavioral health, primary and specialty care, and ongoing care navigation. The Cigna Group's advantage comes from its ability to engage patients across more of that journey than most organizations, creating
visibility into the factors that influence outcomes, affordability and experience. Supporting these patients requires a unique breadth of capabilities, and The Cigna Group's growth platforms work together to understand, anticipate and manage
clinical complexity:
|
•
|
Evernorth Specialty & Care Services:
Supports more than one million patients with complex conditions and delivers more than 8 million prescriptions annually, combining deep clinical expertise, nationwide provider and distribution capabilities, and personalized support
models that improve access, adherence, and outcomes. This combination has established Evernorth as a trusted partner to patients, providers, health systems, and drug manufacturers.
|
|
•
|
Cigna Healthcare: Delivers more
personalized and proactive experiences across the full spectrum of patient requirements, from identifying emerging oncology needs earlier to providing AI-enabled navigation and advocacy support.
|
|
•
|
Evernorth Pharmacy Benefit Services: Integrates pharmacy benefits, clinical insights, and supply chain expertise to improve affordability, support better adherence, and drive better outcomes at scale.
|
Together, these capabilities enable The Cigna Group to identify risk earlier, connect fragmented information across the health care system, and intervene before
higher-cost events occur. This ability to understand and manage complexity creates a meaningful advantage in affordability, personalization and outcomes, while positioning the Company to capture a growing share of one of health care's largest and
fastest-growing segments.
Evanko continued, “The capabilities that make us a leader in complex care are also being applied to improve how health care is experienced across the broader population.
By bringing together data, clinical expertise and AI through our health intelligence engine, we can identify needs earlier, personalize support and help lower the total cost of care. As we continue to scale these capabilities, we will create value
for customers, clients and shareholders alike through better outcomes, lower costs and a more connected health care experience.”
As part of its commitment to supporting people living with complex conditions, The Cigna Group Foundation is announcing a new $10.5 million, three-year grant program to
expand community support for patients and caregivers and help address non-clinical barriers to treatment. The program will focus on strengthening the services and support systems that help patients start, stay on and benefit from treatment,
including care navigation, education, peer support, mental health resources and assistance with essential social needs.
2
Execute with discipline
The Cigna Group will continue to fuel sustainable growth through operational excellence, expense discipline, and capital flexibility enabled by the Company’s
capital-light model.
Reaffirms 2026 guidance and provides 2030 financial targets
The Cigna Group reaffirms its 2026 financial guidance:
|
•
|
Consolidated Adjusted Revenues of ~$280 billion
|
|
•
|
Consolidated Adjusted EPS of at least $30.45
|
|
•
|
Evernorth Health Services pre-tax adjusted income from operations of at least $6.90 billion
|
|
•
|
Cigna Healthcare pre-tax adjusted income from operations of at least $4.55 billion
|
|
•
|
Medical care ratio of 83.7% to 84.7%
|
The Cigna Group provides 2026 – 2030 financial targets:
(All financial targets are through year end 2030 unless otherwise noted)
|
•
|
10-14% Adjusted EPS CAGR
|
|
•
|
~$50 billion in cumulative operating cash flow
|
As part of its Lead to One direction, The Cigna Group is announcing a new $3 billion multi-year series of modernization and productivity initiatives to support growth and
financial performance. The initiatives will focus on modernizing processes and streamlining workflows, empowering colleagues with AI-enabled insights and tools to drive greater effectiveness, along with driving disciplined supplier and vendor
management.
“We are building on a proven track record of delivering consistent and differentiated adjusted EPS growth through disciplined execution,” said Ann Dennison, Executive
Vice President and Chief Financial Officer of The Cigna Group. “Our long-term growth targets are supported by our clear growth pillars, distinct capabilities, and our new multi-year modernization and productivity initiatives, which will self-fund
and fuel our performance. We are positioned to deliver attractive, sustainable growth, robust operating cash flow, and enhanced shareholder returns.”
Webcast information
The event will begin at 8:30 a.m. ET. A live webcast of the presentation will be available at https://www.thecignagroupinvestorday.com.
To listen to this presentation live on the Internet, visit https://www.thecignagroupinvestorday.com at least 15 minutes prior to the presentation to download and install
any necessary audio software.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly
challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in
more than 30 markets and jurisdictions and has over 180 million customer relationships around the world. Learn more at thecignagroup.com
3
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based
on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted
revenue for 2026; projected adjusted income from operations for 2026 on a segment basis, projected adjusted earnings per share and earnings per share growth rate for 2026 and future periods for The Cigna Group, Evernorth Health Services (including
Pharmacy Benefit Services and Specialty & Care Services) and Cigna Healthcare; projected medical care ratio for 2026; projected cash flow from operations; future financial or operating performance, including our ability to improve the health
and vitality of those we serve; our market opportunities; economic, regulatory or competitive environments; future growth (including growth of Evernorth Health Services and Cigna Healthcare), business strategy, and strategic or operational
initiatives, including our modernization and productivity initiatives, and ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; our prospects for growth in the
coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as
"believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or
implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result
in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly
changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain
relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to
expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with
managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in
government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data
laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our
information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence
on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational
operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations;
which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics,
stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk
related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You
should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict
or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.
4
Notes
Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Cigna Group defines adjusted revenues as
total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are
matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or
future underlying performance of the business. Adjusted revenues are not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues.
Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the underlying results
of operations of The Cigna Group’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income (or income before taxes
less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s share of certain investment results
of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring
operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not
determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.
Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income or adjusted revenues to total revenues on a
forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various
factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.
The Cigna Healthcare medical care ratio represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or
experience-rated funding arrangements. Changes in percentages may be expressed in basis points.
5
The Cigna Group’s outlook excludes the potential effects of any business combinations that may occur after the date of this press release. The Cigna Group’s outlook
includes the potential effects of expected future share repurchases and anticipated 2026 dividends.
The Cigna Group currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination
that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on The Cigna Group’s financial position,
results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.
The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of
capital. The share repurchase program may be affected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated
transactions. The program may be suspended or discontinued at any time.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
Ralph.Giacobbe@TheCignaGroup.com
Media Contact
Justine Sessions
1 (860) 810-6523
Justine.Sessions@Evernorth.com
6